CIGB-258

an immunomodulatory peptide derived from HSP60

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Link	Tested on	Impact factor	Notes	Publication date
CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients IL-6 Severe severity Cytokine storm Preprint Peptide Critical severity	Patients			Jun/02/2020

Link	Publication date
CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients	May/24/2022